Every 8-K that Xeris Biopharma Holdings (XERS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XERS filings page.
Xeris Biopharma Holdings reported strong growth for the three and six months ended June 30, 2026. Second quarter total revenue was $92.1 million, up 29% from $71.5 million a year earlier, driven by net product revenue of $91.0 million, which grew 34%. Recorlev revenue rose 81% to $56.8 million, while Gvoke slipped 4% and Keveyis grew 2%. Gross margin improved to 86% from 82%.
For the first half of 2026, total revenue reached $175.2 million, up 33%, with net product revenue of $173.5 million, up 38%. Adjusted EBITDA, a non-GAAP measure, was $19.3 million in the quarter and $34.4 million year-to-date, both higher than 2025. GAAP net loss widened to $31.1 million in the quarter and $28.9 million year-to-date, largely due to a one-time, non-cash charge of about $31 million related to 2028 Convertible Notes exchange agreements. Cash and cash equivalents were $121.7 million at June 30, 2026, and total shares outstanding were 182.3 million at July 31, 2026.
Xeris eliminated all outstanding 8.00% Convertible Senior Notes due 2028 by exchanging approximately $23.0 million of notes for $23.0 million in cash and about 5.0 million shares, and through conversion of another $10.5 million into about 3.6 million shares. The company tightened its 2026 total revenue guidance to $385–$390 million. It also received a Notice of Allowance for a new Keveyis patent expected to extend protection through at least 2039 and secured a new U.S. patent for its XP-8121 hypothyroidism candidate.
On July 15, 2026, Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions with certain holders of its 8.00% Convertible Senior Notes due 2028. These holders exchanged approximately $23 million in aggregate principal amount of the notes for approximately 5.0 million shares of common stock and approximately $23 million in cash, funded with liquidity on-hand, and the exchanged notes were immediately cancelled.
Separately, a holder of $10.5 million in principal amount of the 2028 notes elected to convert those notes into approximately 3.6 million shares of common stock. After the exchange transactions and this conversion, no 2028 notes remain outstanding. Shares issued in the exchanges relied on the Section 4(a)(2) exemption under the Securities Act, while shares issued in the conversion relied on Section 3(a)(9), with exchanging noteholders representing accredited investor and qualified institutional buyer status.
Xeris Biopharma Holdings is changing its board structure and adding new expertise. The Board increased its size from seven to eight members and appointed Nerissa Kreher, M.D. as a Class III director, effective July 1, 2026, with a term running to the 2027 annual meeting. In connection with her appointment, she received an initial equity award of stock options and restricted stock units with a combined grant date fair value of about $450,000, and she will be eligible for annual equity awards of about $300,000 starting with the 2027 annual meeting, under the non-employee director compensation program.
The Board also named Chief Executive Officer John Shannon as Chairperson of the Board, effective July 1, 2026, and designated Marla S. Persky as Lead Independent Director. These moves consolidate leadership at the CEO level while maintaining a defined independent leadership role on the board.
Xeris Biopharma Holdings entered into privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028. The company will retire approximately $23 million in aggregate principal amount of these notes in exchange for $23 million in cash plus shares of common stock, with the share amount based on the 21‑day volume‑weighted average price starting June 11, 2026.
The company expects the exchange to close on or about July 15, 2026, funded with existing liquidity. Following the exchange, $10.5 million principal of the notes will remain outstanding. A related press release states this will eliminate about $23 million of debt and reduce annual interest expense by roughly $2 million, and, assuming a share price of $6.71, Xeris estimates issuing about 4.6 million shares.
Xeris Biopharma Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 172,625,762 common shares entitled to vote as of April 14, 2026, 128,268,073 were represented, establishing a quorum. Stockholders elected Class II directors Dawn Halkuff and John Johnson by plurality vote.
They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers under the Say‑on‑Pay Vote. No other matters were submitted for stockholder action.
Xeris Biopharma Holdings, Inc. reported a strong first quarter of 2026 with total revenue of $83.1 million, up 38% from $60.1 million a year earlier. Net product revenue rose 43% to $82.5 million, driven mainly by Recorlev, whose net revenue increased 95% to $49.8 million, while Gvoke was flat and Keveyis grew 4%.
Gross margin improved to 87% from 85%. Operating expenses increased as the company invested in R&D for XP-8121 and expanded its commercial organization, particularly for Recorlev. Despite higher costs, Xeris generated net income of $2.2 million, compared with a net loss of $9.2 million in the prior-year quarter, and Adjusted EBITDA increased to $15.1 million from $4.4 million.
The company tightened full-year 2026 total revenue guidance to a range of $380 million to $390 million, which it states represents more than 30% growth at the midpoint, and highlighted plans to initiate a Phase 3 trial of XP-8121 later in 2026.
Xeris Biopharma Holdings, Inc. reported that Dr. Jeffrey Sherman will retire from its Board of Directors and will not stand for reelection at the 2026 Annual Meeting of Stockholders. He has served as a director since 2021 and sits on the Compensation Committee and the Nominating and Corporate Governance Committee.
The company stated that Dr. Sherman’s decision is not due to any disagreement regarding operations, policies, or practices. When his term ends at the 2026 Annual Meeting, the Board size will be reduced from eight to seven directors.
Xeris Biopharma reported record results for the fourth quarter and full year 2025 and issued strong 2026 guidance. Fourth quarter total revenue rose to $85.8 million from $60.1 million, driven by Recorlev, Gvoke and Keveyis growth, and net income reached $11.1 million versus a prior-year net loss of $5.1 million.
For 2025, total revenue increased to $291.8 million from $203.1 million, with Recorlev sales more than doubling. The company generated full-year net income of $0.6 million, a sharp improvement from a $54.8 million loss in 2024. Adjusted EBITDA improved to $59.4 million from $1.2 million, reflecting higher sales and operating leverage.
For 2026, Xeris expects total revenue between $375 million and $390 million, implying more than 30% growth at the midpoint, and projects higher R&D and SG&A to support XP-8121 Phase 3 development and Recorlev investment while increasing Adjusted EBITDA versus 2025.
Xeris Biopharma Holdings, Inc. filed a current report to disclose that it has issued a press release with certain preliminary financial results for the fourth quarter and full year ended December 31, 2025. The press release is provided as Exhibit 99.1 and offers an early view of the company’s recent performance before final audited figures are available. The company states that this financial information, including Exhibit 99.1, is being furnished rather than filed, which affects how it is treated under securities laws.
Xeris Biopharma Holdings, Inc. furnished an 8-K announcing a press release with results of operations and business highlights for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth.